Litigation Details for CenterWell Pharmacy, Inc.v. Celgene Corporation (S.D.N.Y. 2024)
✉ Email this page to a colleague
CenterWell Pharmacy, Inc.v. Celgene Corporation (S.D.N.Y. 2024)
| Docket | 1:24-cv-06924 | Date Filed | 2024-09-13 |
| Court | District Court, S.D. New York | Date Terminated | |
| Cause | 15:2 Antitrust Litigation | Assigned To | Edgardo Ramos |
| Jury Demand | Plaintiff | Referred To | |
| Patents | 10,555,939; 6,281,230; 6,555,554; 7,968,569; 8,198,262; 8,648,095; 8,673,939; 8,735,428; 8,828,427; 9,993,467 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in CenterWell Pharmacy, Inc.v. Celgene Corporation
The small molecule drugs covered by the patents cited in this case are ⤷ Start Trial and ⤷ Start Trial .
Details for CenterWell Pharmacy, Inc.v. Celgene Corporation (S.D.N.Y. 2024)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2024-09-13 | External link to document | |||
| 2024-09-13 | 1 | Complaint | digits: formulation patent 10,555,939, discussed infra). The formulation patent is referred to as the… All the formulation patents at issue (the 8,828,427, 9,993,467, and 10,555,939) are related to this … 264. Patent application no. 15/976,808 would eventually lead to the 10,555,939. The ’5939 is…-acquired patent is not patentably distinct from the invention claimed in an earlier patent (and no exception…Prior art” refers to patents, published patent applications, and other non-patent sources, such as journal | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
